Clinical Trials Logo

Pancreatic Insufficiency clinical trials

View clinical trials related to Pancreatic Insufficiency.

Filter by:

NCT ID: NCT01851694 Recruiting - Cystic Fibrosis Clinical Trials

Beta-cell Response to Incretin Hormones in Cystic Fibrosis

Start date: May 2013
Phase: N/A
Study type: Interventional

In recent years, diabetes has emerged as one of the most significant co-diseases that many Cystic Fibrosis (CF) patients develop. Type 1 (T1D) and Type 2 (T2D) diabetes results when either the body does not make enough insulin or the body does not respond correctly to this insulin, respectively. Insulin is a hormone which is made by cells in the pancreas and helps carry glucose (sugar) from the food we eat to the cells of the body for energy. While cystic fibrosis related diabetes (CFRD) has many features similar to both T1D and T2D, patients with CF may not have the same symptoms as either T1D or T2D patients. Currently, there is little understanding of CFRD and the best options for treatment remain unclear. The purpose of this research study is to examine and understand the various mechanisms that contribute to CFRD and gain a better understanding of potential means to treat CFRD. In particular, we plan to study the effects of incretin hormones that can enhance insulin production in CF patients. Enrollment is complete for the protocol as initially written. In order to further study the role of the incretin hormone on Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) function , we have received approval to extend our investigation to include the following study groups: - Cystic Fibrosis participants with normal glucose tolerance - Non-Cystic Fibrosis controls

NCT ID: NCT01710644 Completed - Cystic Fibrosis Clinical Trials

Efficacy and Tolerability of NM-BL in Patients With Exocrine Pancreatic Insufficiency Due to Cystic Fibrosis

Start date: May 2013
Phase: Phase 1/Phase 2
Study type: Interventional

The purpose of this Randomized, Double-blind, Multicenter, Two-period Crossover Study is to Assess the Efficacy and Tolerability of Burlulipase (NM-BL) in Patients with Exocrine Pancreatic Insufficiency due to Cystic Fibrosis

NCT ID: NCT01144507 Completed - Cystic Fibrosis Clinical Trials

Prediction by Ultrasound of the Risk of Hepatic Cirrhosis in Cystic Fibrosis

PUSH
Start date: January 12, 2010
Phase:
Study type: Observational

The specific aims for this study are: 1. To determine if sonographic findings predict the risk of progression of liver disease to cirrhosis by comparing cystic fibrosis subjects with heterogeneous echogenicity pattern on ultrasound to those with normal echogenicity pattern on ultrasound 2. To develop a database and biorepository of serum, plasma, urine and DNA to aid the investigations in ascertaining the mechanisms, consequences, genetic risk factors and biomarkers for the development of cirrhosis 3. To determine if there are differences in health related quality of life, pulmonary or nutritional status in children with cystic fibrosis who have a heterogeneous echo pattern on ultrasound compared to those who have a normal echo pattern on ultrasound 4. To determine if Doppler velocity measurements of hepatic and splenic vessels predict an increased risk for the development of cirrhosis. 5. To determine if cirrhosis on ultrasound progresses to portal hypertension during the study period 6. To determine if homogeneous liver progresses to either cirrhosis or heterogeneous liver. 7. To determine the frequency of complications of portal hypertension during follow up in those identified with cirrhosis by year 6 of the study

NCT ID: NCT01012908 Active, not recruiting - Clinical trials for Pancreatic Insufficiency

Clinical Non-Inferiority of Pancreatic Enzymes (Norzyme ® - Bergamo) Compared To Creon ® (Solvay Pharmaceutical) in Patients With Exocrine Pancreatic Insufficiency

Start date: March 2010
Phase: Phase 2/Phase 3
Study type: Interventional

The primary objective of this clinical trial is to demonstrate non-inferiority clinical development of pancreatic enzymes from Laboratory Bergamo (Norzyme ®) in relation to pancreatic enzymes from Solvay Pharmaceuticals (Creon ®), by comparing the average amount of lipids in the feces of 72 hours after 14 days of treatment with each drug.

NCT ID: NCT00880100 Completed - Cystic Fibrosis Clinical Trials

Use of Ultrase® MT12 in Young Cystic Fibrosis Children (CF)

Start date: April 2009
Phase: Phase 3
Study type: Interventional

Multicenter, explorative, phase IIIb, open-label study to assess the efficacy and safety of Ultrase® MT12, in the control of steatorrhea and clinical signs and symptoms of malabsorption in CF children with pancreatic insufficiency (PI). This study is sponsored by Aptalis Pharma (formerly Axcan).

NCT ID: NCT00763412 Completed - Clinical trials for Pancreatic Insufficiency

Pilot and Feasibility Study for the Treatment of Pre-diabetes in Patients With Cystic Fibrosis

Start date: November 2006
Phase: N/A
Study type: Interventional

The purpose of this study is to provide the necessary data and experience to design a larger, full scale clinical trial to determine if a certain medicine (repaglinide), which increases the amount of insulin secreted by the pancreas, can improve the nutritional status and pulmonary function of adolescents and young adults with cystic fibrosis and prediabetes by improving blood glucose control. The investigators are also trying to determine the relationship between systemic inflammatory factors and glucose impairment.

NCT ID: NCT00705978 Completed - Clinical trials for Pancreatic Insufficiency

Creon 40,000 for Treatment of PEI (Pancreatic Exocrine Insufficiency) Due to Chronic Pancreatitis

Start date: June 2008
Phase: Phase 3
Study type: Interventional

This study will provide efficacy data for Creon 40,000 in CP subjects as well as long-term safety data. During the long-term treatment with Creon 40,000 nutritional parameters will be assessed and correlated with CFA.

NCT ID: NCT00572975 Completed - Cystic Fibrosis Clinical Trials

Malabsorption Blood Test:Toward a Novel Approach to Quantify Steatorrhea

MBT
Start date: August 2006
Phase: Phase 4
Study type: Interventional

*The purpose of this study is to develop a more accurate, reliable, specific and more acceptable alternative clinical test to the 72-hour stool and diet collection for quantifying fat malabsorption in people with CF and pancreatic insufficiency.

NCT ID: NCT00535756 Completed - Clinical trials for Pancreatic Insufficiency

Creon After Pancreatic Surgery

Start date: April 2008
Phase: Phase 4
Study type: Interventional

This study will provide efficacy data for Creon 25000 MMS in PS patients as well as long-term safety data. During the long-term treatment with Creon 25000 nutritional parameters will be assessed and correlated with CFA

NCT ID: NCT00513682 Completed - Cystic Fibrosis Clinical Trials

Efficacy and Safety of Ultrase® MT20 in Improving the Coefficient of Fat Absorption (CFA) in Children With Cystic Fibrosis (CF) and Pancreatic Insufficiency (PI)

Start date: July 2007
Phase: Phase 3
Study type: Interventional

This is a Phase III, multicenter, open-label study, that will evaluate the improvement of nutrient absorption when participants will receive Ultrase® MT20. This study is sponsored by Aptalis (formerly Axcan). This study is performed in children from 7 to 11 years old.